Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
暂无分享，去创建一个
J. Cayuela | P. Szankasi | B. Druker | M. Heinrich | M. Deininger | C. Tognon | J. Tyner | T. Kelley | T. O'hare | H. Than | Dong-Wook Kim | C. Eide | N. Vellore | Anna Reister Schultz | A. Senina | A. Pomicter | P. Clair | D. Yan | W. Qiang | M. Zabriskie | D. Réa | Samantha L Savage Stevens | Amber D Bowler | Orlando Antelope